Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer

NCT03272217 is registered in ClinicalTrials.gov with Arjun Balar, MD as lead sponsor.

NCT NCT03272217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03272217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Lead sponsor
Arjun Balar, MD
Phase
Phase 2
Overall status
Terminated
Start date
September 13, 2017
Completion date
March 17, 2022
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma